XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will share new discoveries from their basic science ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...

Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...

Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...

Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited announced that the Hong Kong Department ...